Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced today that its management team will participate in two investor conferences in May 2026: the RBC Capital Markets Global Healthcare Conference on May 19 in New York and A.G.P.’s Annual Virtual Healthcare Conference on May 20. The company’s participation underscores its commitment to engaging with the investment community as it advances its portfolio of central nervous system (CNS) and immunology treatments.
Tonix recently achieved a major milestone with the approval of TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. This flagship product is now part of Tonix’s CNS commercial infrastructure, which also includes marketed acute migraine products Zembrace® SymTouch® and Tosymra®. The company is leveraging the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
Beyond TONMYA, Tonix’s CNS pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease with high unmet need. In the immunology space, the company is advancing monoclonal antibody candidates TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs highlight Tonix’s strategic focus on areas where existing therapies are limited.
The investor conferences provide a platform for Tonix to discuss its commercial strategy, pipeline progress, and financial outlook. The company noted that its participation aims to increase visibility among institutional investors and analysts. Details on presentations, including webcast information if available, will be announced closer to the event dates.
For more information about Tonix Pharmaceuticals, visit the company’s newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/ZZpG2.
